Alteon To Present at The BIO CEO & Investor Conference 2005
February 10 2005 - 8:15AM
PR Newswire (US)
Alteon To Present at The BIO CEO & Investor Conference 2005 -
Presentation to be Webcast - PARSIPPANY, N.J., Feb. 10
/PRNewswire-FirstCall/ -- Alteon Inc. (AMEX:ALT) announced today
that Kenneth I. Moch, President & Chief Executive Officer, will
present at the BIO CEO & Investor Conference, Wednesday,
February 23, 2005, 3:30 pm, ET, at The Waldorf-Astoria, New York,
NY. Mr. Moch will discuss the clinical objectives for the ongoing
Phase 2 programs of alagebrium in systolic hypertension, heart
failure and erectile dysfunction, as well as provide an update of
2005 milestones. The presentation will be webcast and can be viewed
at the investor relations section of Alteon's website,
http://www.alteon.com/. It will be archived there after the event.
Note to BIO attendees: Alteon will be available for one-on-one
meetings. Please arrange through BIO or by calling Susan
Pietropaolo at 201-818-5537. About Alteon Alteon is developing
several new classes of drugs that have shown the potential to
reverse or slow down diseases of aging and complications of
diabetes. These compounds appear to have an impact on a fundamental
pathological process caused by the progressive formation of
protein-glucose complexes called Advanced Glycation End-products
(A.G.E.s). The formation and crosslinking of A.G.E.s lead to a loss
of flexibility and function in body tissues and organs and have
been shown to be a causative factor in many age- related diseases
and diabetic complications. Alteon has created a library of novel
classes of compounds targeting the A.G.E. pathway. Alteon's lead
compound alagebrium chloride (formerly ALT-711), the only A.G.E.
Crosslink Breaker in advanced human testing, has demonstrated
safety and efficacy in several Phase 2 trials and is actively being
developed for systolic hypertension, heart failure and erectile
dysfunction. Over 1200 patients have been involved in alagebrium's
human clinical trials to date, of whom approximately 900 have
received active compound. Ongoing clinical trials include the Phase
2b systolic hypertension trial, SPECTRA (Systolic Pressure Efficacy
and Safety Trial of Alagebrium), the Phase 2a heart failure trial,
PEDESTAL (Patients with Impaired Ejection Fraction and Diastolic
Dysfunction: Efficacy and Safety Trial of ALagebrium), the Phase 2a
trial EMERALD (Evaluation of Alagebrium in Erectile Dysfunction in
Diabetic Males on PDE5 Inhibitors), as well as a fourth trial
exploring mechanism of action in endothelial dysfunction. For more
detailed information about alagebrium, please visit the scientific
publications section of the Alteon website, http://www.alteon.com/.
Any statements contained in this press release that relate to
future plans, events or performance are forward-looking statements
that involve risks and uncertainties including, but not limited to,
those relating to technology and product development (including the
possibility that early clinical trial results may not be predictive
of results that will be obtained in large-scale testing or that any
clinical trials will not demonstrate sufficient safety and efficacy
to obtain requisite approvals or will not result in marketable
products), regulatory approval processes, intellectual property
rights and litigation, competitive products, ability to obtain
financing, and other risks identified in Alteon's filings with the
Securities and Exchange Commission. The information contained in
this press release is accurate as of the date indicated. Actual
results, events or performance may differ materially. Alteon
undertakes no obligation to publicly release the result of any
revision to these forward-looking statements that may be made to
reflect events or circumstances after the date hereof or to reflect
the occurrence of unanticipated events. DATASOURCE: Alteon Inc.
CONTACT: Susan M. Pietropaolo, Director, Corporate Communications
& Investor Relations, +1-201-818-5537, Web site:
http://www.alteonpharma.com/
Copyright
Ishares Diversified Alternatives Trust (AMEX:ALT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Ishares Diversified Alternatives Trust (AMEX:ALT)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Ishares Diversified Alternatives Trust (American Stock Exchange): 0 recent articles
More Alteon , News Articles